SCHEMBL5788955

SCHEMBL5788955

O=C(OC(=O)C1CCCCC1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.58
POLB P06746 2/20 0.58
ATM Q13315 2/20 0.47
HPGD P15428 1/20 0.46
LMNA P02545 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
SCN1A P35498 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN3A Q9NY46 1/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
F2 P00734 1/20 0.45
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TSHR P16473 1/20 0.42
MTNR1A P48039 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401016 0.98 ELANE (0.55) ELANEPOLBATMHPGDLMNA
SCHEMBL29277477 0.93 ELANE (0.56) ELANEPOLBATMLMNAKMT2A
SCHEMBL10405162 0.86 LMNA (0.61) ELANEPOLBATMHPGDLMNA
SCHEMBL27732927 0.84 POLB (0.47) ELANEPOLBHPGDLMNAKMT2A
SCHEMBL28201287 0.83 RAB9A (0.60) ELANEPOLBATMLMNAKMT2A
SCHEMBL27615711 0.83 ELANE (0.47) ELANEPOLBLMNACYP2D6KMT2A
SCHEMBL13268437 0.83 ELANE (0.55) ELANEPOLBATMHPGDLMNA
SCHEMBL28823439 0.81 ELANE (0.47) ELANEPOLBLMNAKMT2AHTT
SCHEMBL775369 0.81 TDP1 (0.48) ELANEPOLBHPGDLMNACYP1A2
Cyclohexane SCHEMBL28376326 0.80 LMNA (0.61) POLBHPGDLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111548483-B Use of Salen manganese complexes in tandem catalytic reactions involving unsaturated anhydride-epoxy copolymers 中国科学技术大学 2021-08-13 CN claimed
CN-111548483-A Use of Salen manganese complexes in tandem catalytic reactions involving unsaturated anhydride-epoxy copolymers 中国科学技术大学 2020-08-18 CN claimed
EP-1100479-B1 MEDICINAL PRODUCTS WITH RETARDED PHARMACOLOGICAL ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF SCHIERHOLZ JOERG DR DR (DE) 2006-01-11 EP claimed
US-3978120-A METHOD FOR THE PRODUCTION OF ALICYCLIC ANHYDRIDES SNIA VISCOSA SOCIETA NAZIONALE INDUSTRIA APPLICAZIONI VISCOSA S.P.A. (IT) 1976-08-31 US claimed
US-12620622-B2 Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same DAIKIN INDUSTRIES, LTD. (JP) 2026-05-05 US disclosed
US-20250260063-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2025-08-14 US disclosed
EP-3780232-B1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE DAIKIN IND LTD (JP) 2025-07-30 EP disclosed
US-20250174720-A1 ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE DAIKIN INDUSTRIES, LTD. (JP) 2025-05-29 US disclosed
US-12315885-B2 Electrolytic solution, electrochemical device, lithium-ion secondary battery, and module DAIKIN INDUSTRIES, LTD. (JP) 2025-05-27 US disclosed
EP-4553940-A1 SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2025-05-14 EP disclosed
EP-4553918-A1 NEGATIVE ELECTRODE, BATTERY, AND METHOD FOR COVERING BATTERY MATERIAL DAIKIN INDUSTRIES, LTD. (JP) 2025-05-14 EP disclosed
EP-4546456-A1 SURFACE TREATMENT AGENT FOR ELECTRODE MATERIAL, POSITIVE ELECTRODE ACTIVE MATERIAL, CURRENT COLLECTOR FOIL, NEGATIVE ELECTRODE ACTIVE MATERIAL, CONDUCTIVE AID, ELECTRODE, BATTERY, METHOD FOR MANUFACTURING POSITIVE ELECTRODE ACTIVE MATERIAL, METHOD FOR MANUFACTURING CURRENT COLLECTOR FOIL, METHOD FOR MANUFACTURING NEGATIVE ELECTRODE ACTIVE MATERIAL, METHOD FOR MANUFACTURING CONDUCTIVE AID, AND METHOD FOR MANUFACTURING ELECTRODE DAIKIN INDUSTRIES, LTD. (JP) 2025-04-30 EP disclosed
CN-110546940-A Imaging device and laminate FUJIFILM CORP 2019-12-06 CN disclosed
CN-101140387-A Liquid crystal display device FUJIFILM CORP (JP) 2008-03-12 CN disclosed
EP-0534443-B1 3,6-Disubstituted pyridazine derivatives MITSUBISHI CHEM CORP (JP) 1998-12-30 EP disclosed
US-5462941-A 1-(cyclohexylalkylamino)-4-(phenyl, thienyl, or furyl) phthalazines; anti-platelet agglutination agents for treatment or prevention of cerebro- or cardiovascular disorders MITSUBISHI CHEMICAL CORPORATION (JP) 1995-10-31 US disclosed
EP-0534443-A1 3,6-Disubstituted pyridazine derivatives Mitsubishi Chemical Corporation (JP) 1993-03-31 EP disclosed
US-4349473-A Process for the preparation of ω-lactams, in particular caprolactam SNIA VISCOSA SOCIETA' NAZIONALE INDUSTRIA APPLICAZIONI VISCOSA S.P.A (IT) 1982-09-14 US disclosed
US-4262157-A USING A DIAZABICYCLOALKENE ABBOTT LABORATORIES (US) 1981-04-14 US disclosed
US-3978120-A METHOD FOR THE PRODUCTION OF ALICYCLIC ANHYDRIDES SNIA VISCOSA SOCIETA NAZIONALE INDUSTRIA APPLICAZIONI VISCOSA S.P.A. (IT) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250174720-A1 ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE HCN2, HCN1, HCN3 ELANE 968/4885POLB 1828/4885ATM 3222/4885
US-12620622-B2 Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same ASH2L, OLA1, ODC1 ELANE 2779/4885POLB 1383/4885ATM 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.